ArticleNeuroradiology2026
Safety and efficacy of the pipeline vantage flow diverter in small cerebral vessels ≤2.5 mm: a case series.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Pipeline Vantage Flow Diverter (PVFD) with shield technology is the fourth and latest generation of the Pipeline embolization devices which are flow diverting stents used in the treatment of cerebral aneurysms. In early 2025 the larger PVFD 027s were recalled due to concerns of braid deformities with updated instructions provided for the PVFD 021. This study aimed at evaluating the safety and efficacy of the PVFD for cerebral aneurysm treatment in small parent vessels ≤ 2.5 mm.
methodsA retrospective review of patients who received a 2.5 mm diameter PVFD for cerebral aneurysm treatment at our institution over 4 years was performed. Baseline patient characteristics, complications, clinical and radiological outcomes were collected for each patient with a mean follow up duration of 1 year and 17 days (median 7 months and 5 days).
resultsThere were a total of 14 patients identified with a total of 16 aneurysms treated. At latest follow up complete aneurysm occlusion was achieved in 10 (66.7%) out of 16 treated aneurysms with 1 patient still awaiting follow up imaging. There were 2 (14.3%) of 14 patients who had immediate neurological complications, of which 1 was a transient deficit, and 0 patients with delayed complications. In-stent stenosis was found in 2 (15.4%) of 13 patients and asymptomatic stent occlusion occurred in 1 patient (7.69%).
conclusionsThis case series demonstrated an acceptable safety profile with reasonable aneurysm occlusion rates for the use of PVFD in cerebral vessels ≤ 2.5 mm in treating aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.